StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

Research analysts at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

Shares of AKTX stock opened at $0.98 on Thursday. Akari Therapeutics has a fifty-two week low of $0.90 and a fifty-two week high of $4.40. The stock’s fifty day moving average is $2.05 and its two-hundred day moving average is $2.82.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.